US/UK/Canada

Share

Pick a time period -
Tags ( Active)

NOTICE OF ANNUAL GENERAL MEETING IN asarina pharma AB (publ)

The shareholders of Asarina Pharma AB (publ) (the “Company”) are hereby summoned to attend the Annual General Meeting (“AGM”) on 5 May 2020, at 10.00 CEST at Erik Penser Bank, Apelbergsgatan 27 in Stockholm, Sweden. Registration starts at 09.30 CEST and will stop when the meeting starts. NOTE: This is an unofficial translation of the original notice, which is in Swedish. In case of discrepancies, the Swedish version shall prevail.The Company is closely monitoring the development of covid-19, the corona virus, and will revert with more information closer to the AGM if it is deemed

Asarina Pharma issues new shares to Ergomed plc

(Stockholm, 20 February, 2020) Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) today announces that it will, pursuant to the authorisation granted by the Annual General Meeting on 21 January 2020, issue 301,724 new shares to Ergomed plc (“Ergomed”), the CRO carrying out Asarina Pharma’s phase IIb PMDD study.The share issue is triggered by the achievement of a milestone in the PMDD study, and it represents 1.6% of the current share capital in Asarina Pharma. The current payment to Ergomed amounts to SEK 8,387,927.20 and the number of shares has been determined at the market

First patient dosed in landmark Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) has administered the first dose in its Phase IIa trial of a new, preventative treatment for menstrual migraine. Sepranolone is the first woman-only migraine treatment, specifically targeting menstrual migraine.Globally, three times more women than men suffer from migraine. Approximately 50 million of those also suffer from menstrual migraine, a more severe form highly resistant to standard treatments, including recently developed CGRP antibodies. Sepranolone is the first compound to target this highly frequent form of female migraine. If

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe